1. Scrip

Trials In Focus: A Call For Incentives To Help Drive Trial Diversity

 
• By Alaric DeArment

Panelists at the BIO CEO & Investor meeting talked about ways to improve trial diversity. Also, GSK and Pfizer released retrospective analyses of diversity in their trials, while J&J is working to improve diversity with Stand Up To Cancer.

• Source: Shutterstock

The Food and Drug Omnibus Reform Act, signed at the end of 2022 amid heightened attention to the importance of clinical trials enrolling diverse populations, requires clinical trial sponsors to submit “diversity action plans” for late-stage drug and device studies. But panelists at the recent BIO CEO & Investor Conference suggested more needs to happen for diversity to become the norm, including an effort by the entire health care sector and incentives to encourage diversity.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

UK Promises To ‘Turbo-Charge’ Clinical Trials As Tariff Threat Remains

 
• By Andrew McConaghie

Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.